ArticleNPJ precision oncology2025
Multi-modal characterization of metabolic and immune gene clusters in adrenocortical carcinoma treatment.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ABCC9/SUR2 has a Complex Expression Pattern in Human Brain Gliovascular Unit Cells, Including Astrocytes.Journal of molecular neuroscience : MN · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Adrenocortical carcinoma (ACC) is an uncommon and aggressive endocrine malignancy, characterized by limited therapeutic options and considerable variability in patient outcomes. The challenge is to combine the complex information of ACC with artificial intelligence (AI) and clinical and pathology data to achieve precision medicine and improve patient prognosis. We developed the Steroid-related Immune Score (SIS) using multi-modal analysis of genomics, digital pathology, and artificial intelligence and validated it in external datasets. In addition, we conducted single-cell RNA sequencing (scRNA-seq) of small samples and in vitro functional experiments. SIS delivered a stable performance with an AUC of 0.8 ± 0.01 in the ResNet50 and Vision Transformer-B16 models. We validated the best model in external ACC cohorts. Using Class Activation Maps (CAMs) technology revealed that SIS was associated with lymphocyte infiltration, establishing it as a new feature in addition to the Weiss scoring system. Patients in the high SIS group responded well to immunotherapy, while the low SIS group showed adaptability to hormone inhibition therapy. Single-cell RNA sequencing data revealed the relationship between the tumor microenvironment and drug resistance in ACC. In vitro functional assays demonstrated that elevated DHCR7 gene expression correlated with unfavorable prognosis and treatment sensitivity, identifying it as a prospective therapeutic target. Furthermore, there are similarities between the metabolic characteristics of ACC and schizophrenia, such as calcium and iron ion levels. Our multi-modal analysis comprehensively characterizes the immune microenvironment of ACC, emphasizing the synergistic regulation of metabolic and immune gene clusters that influence ACC patients' responses to immune and hormone therapies.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.